AI-Driven Drug Discovery in the AlphaFold Era

AlphaFold2 solved the protein folding problem in 2020. AlphaFold3 in 2024 enables prediction of how any molecule binds to any protein target. Recursion Pharmaceuticals identified 40 novel drug candidates via 2.2 million simulations. Insilico Medicine advanced the first AI-designed drug to Phase 2 in 2023. By 2030 analysts project AI will identify over 50 percent of new drug candidates, cutting drug discovery from 5 years to under 2.